DeFronzo RA - Search Results

1

Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans.

Abdul-Ghani MA, DeFronzo RA, Norton L. Abdul-Ghani MA, et al. Among authors: defronzo ra. Diabetes. 2013 Oct;62(10):3324-8. doi: 10.2337/db13-0604. Diabetes. 2013. PMID: 24065789 Free PMC article.

2

Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes.

Pratipanawatr T, Cusi K, Ngo P, Pratipanawatr W, Mandarino LJ, DeFronzo RA. Pratipanawatr T, et al. Among authors: defronzo ra. Diabetes. 2002 Feb;51(2):462-8. doi: 10.2337/diabetes.51.2.462. Diabetes. 2002. PMID: 11812756

3

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.

Miyazaki Y, Matsuda M, DeFronzo RA. Miyazaki Y, et al. Among authors: defronzo ra. Diabetes Care. 2002 Mar;25(3):517-23. doi: 10.2337/diacare.25.3.517. Diabetes Care. 2002. PMID: 11874940 Clinical Trial.

4

Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes.

Bajaj M, Pratipanawatr T, Berria R, Pratipanawatr W, Kashyap S, Cusi K, Mandarino L, DeFronzo RA. Bajaj M, et al. Among authors: defronzo ra. Diabetes. 2002 Oct;51(10):3043-8. doi: 10.2337/diabetes.51.10.3043. Diabetes. 2002. PMID: 12351445 Clinical Trial.

5

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA. Bajaj M, et al. Among authors: defronzo ra. Diabetes. 2003 Jun;52(6):1364-70. doi: 10.2337/diabetes.52.6.1364. Diabetes. 2003. PMID: 12765945

6

Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.

Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. Among authors: defronzo ra. Diabetes. 2003 Aug;52(8):1943-50. doi: 10.2337/diabetes.52.8.1943. Diabetes. 2003. PMID: 12882909 Clinical Trial.

7

Ceramide content is increased in skeletal muscle from obese insulin-resistant humans.

Adams JM 2nd, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC, Mandarino LJ. Adams JM 2nd, et al. Among authors: defronzo ra. Diabetes. 2004 Jan;53(1):25-31. doi: 10.2337/diabetes.53.1.25. Diabetes. 2004. PMID: 14693694

8

Improving efficacy of diabetes management using treatment algorithms in a mainly Hispanic population.

Fanning EL, Selwyn BJ, Larme AC, DeFronzo RA. Fanning EL, et al. Among authors: defronzo ra. Diabetes Care. 2004 Jul;27(7):1638-46. doi: 10.2337/diacare.27.7.1638. Diabetes Care. 2004. PMID: 15220240

9

Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects.

Wajcberg E, Miyazaki Y, Triplitt C, Cersosimo E, DeFronzo RA. Wajcberg E, et al. Among authors: defronzo ra. Diabetes Care. 2004 Dec;27(12):2868-73. doi: 10.2337/diacare.27.12.2868. Diabetes Care. 2004. PMID: 15562199 Clinical Trial.

10

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. DeFronzo RA, et al. Diabetes Care. 2005 May;28(5):1092-100. doi: 10.2337/diacare.28.5.1092. Diabetes Care. 2005. PMID: 15855572 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

679 results

Search Page

Filters